

Supplementary Table 8. Association of *HSD17B13* rs72613567 and rs6834314 genotypes with clinical outcomes by Cox regression analysis in different genetic models

Genetic model	Genotype	Univariate analysis		Multivariate analysis	
		HR (95% CI)	P-value	HR (95% CI)	P-value
rs72613567					
At least one clinical outcome					
Dominant	T/TA-TA/TA	2.01 (0.99–4.07)	0.052	1.77 (0.86–3.64)	0.122
Co-dominant	T/TA	1.86 (0.86–4.01)	0.115	1.68 (0.77–3.65)	0.191
Co-dominant	TA/TA	2.37 (0.89–6.26)	0.083	1.96 (0.65–5.92)	0.235
Recessive	TA/TA	1.91 (0.78–4.66)	0.154	1.51 (0.55–4.14)	0.426
Liver-related outcome					
Dominant	T/TA-TA/TA	0.61 (0.11–3.31)	0.563	0.06 (0.003–1.43)	0.083
Co-dominant	T/TA	0.42 (0.05–3.77)	0.439	0.11 (0.01–2.13)	0.145
Co-dominant	TA/TA	1.16 (0.13–10.44)	0.897	0.002 (0.00–1.23)	0.048
Recessive	TA/TA	1.42 (0.17–12.25)	0.749	0.02 (0.00–1.25)	0.064
CVS outcome					
Dominant	T/TA-TA/TA	2.34 (0.98–5.58)	0.055	2.77 (1.15–6.69)	0.204
Co-dominant	T/TA	2.26 (0.89–5.72)	0.087	3.81 (1.40–10.34)	0.009
Co-dominant	TA/TA	2.36 (0.71–7.91)	0.163	1.46 (0.40–5.32)	0.568
Recessive	TA/TA	1.79 (0.60–5.31)	0.296	1.18 (0.38–3.71)	0.773
Extrahepatic malignancy					
Dominant	T/TA-TA/TA	5.18 (0.58–46.41)	0.141	4.11 (0.44–38.02)	0.214
Co-dominant	T/TA	5.15 (0.54–49.53)	0.156	21.83 (0.41–1,153.47)	0.128
Co-dominant	TA/TA	4.98 (0.31–80.38)	0.258	8.82 (0.23–342.21)	0.243
Recessive	TA/TA	2.09 (0.23–18.84)	0.510	0.61 (0.03–11.49)	0.738
All-cause mortality					
Dominant	T/TA-TA/TA	2.38 (0.44–13.00)	0.318	1.14 (0.17–7.90)	0.880
Co-dominant	T/TA	2.48 (0.41–14.82)	0.321	4.90 (0.44–54.25)	0.196
Co-dominant	TA/TA	1.85 (0.17–20.40)	0.616	Inf (NA)	0.334
Recessive	TA/TA	1.40 (0.16–12.01)	0.762	0.01 (0.00–0.62)	0.029
rs6834314					
At least one clinical outcome					
Dominant	A/G-G/G	1.80 (0.89–3.64)	0.104	1.49 (0.72–3.09)	0.282
Co-dominant	A/G	1.79 (0.85–3.77)	0.123	1.57 (0.74–3.33)	0.245
Co-dominant	G/G	1.76 (0.57–5.42)	0.324	1.19 (0.32–4.42)	0.791
Recessive	G/G	1.37 (0.48–3.91)	0.560	0.86 (0.26–2.86)	0.801
Liver-related outcome					
Dominant	A/G-G/G	1.12 (0.23–5.55)	0.890	0.28 (0.03–2.25)	0.229
Co-dominant	A/G	0.97 (0.16–5.79)	0.971	0.43 (0.05–3.46)	0.425
Co-dominant	G/G	1.60 (0.16–15.49)	0.688	0.004 (0.00–1.56)	0.070
Recessive	G/G	1.62 (0.19–13.95)	0.662	0.02 (0.00–1.25)	0.064
CVS outcome					
Dominant	A/G-G/G	1.44 (0.62–3.33)	0.395	1.59 (0.68–3.73)	0.286

Supplementary Table 8. Continued

Genetic model	Genotype	Univariate analysis		Multivariate analysis	
		HR (95% CI)	P-value	HR (95% CI)	P-value
Co-dominant	A/G	1.53 (0.64–3.67)	0.345	2.00 (0.80–5.00)	0.137
Co-dominant	G/G	1.06 (0.23–4.85)	0.943	0.89 (0.19–4.15)	0.880
Recessive	G/G	0.92 (0.21–3.95)	0.911	0.64 (0.15–2.83)	0.555
Extrahepatic malignancy					
Dominant	A/G-G/G	4.69 (0.52–41.99)	0.167	3.36 (0.36–31.09)	0.285
Co-dominant	A/G	4.45 (0.46–42.79)	0.196	10.49 (0.44–248.81)	0.146
Co-dominant	G/G	5.63 (0.35–91.17)	0.224	7.72 (0.20–301.97)	0.275
Recessive	G/G	2.47 (0.27–22.27)	0.421	0.62 (0.03–12.11)	0.755
All-cause mortality					
Dominant	A/G-G/G	5.56 (0.65–47.58)	0.117	2.85 (0.30–26.99)	0.360
Co-dominant	A/G	5.80 (0.65–51.90)	0.116	22.62 (0.55–930.41)	0.100
Co-dominant	G/G	4.06 (0.25–64.84)	0.322	Inf (NA)	0.924
Recessive	G/G	1.58 (0.18–13.61)	0.677	0.01 (0.00–0.63)	0.029

Inf (NA) represented number was too large to be recorded.

HSD17B13, 17 β -hydroxysteroid dehydrogenase 13; HR, hazard ratio; CI, confidence interval; CVS, cardiovascular; NA, not available.